Imugene presents new data on cancer vaccines AACR

Company News

by Rachael Jones

Biotech company Imugene (ASX:IMU) presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research Annual Meeting this week.

Dr Tanios Bekaii-Saab from the Mayo Clinic highlighted the key finding of the KEY-Vaxx showing when combined with B-Vaxx its more effective in reducing tumour growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone.

Imugene’s KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect.

Shares in Imugene (ASX:IMU) last traded at 2 cents. 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.